Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Iveric bio
Biotech
Annexon eye disease med failed phase 2 goal—the CEO is thrilled
Annexon's geographic atrophy drug failed to improve lesion growth in phase 2 but did improve vision, which the CEO thinks will support advancement.
Max Bayer
May 24, 2023 4:01pm
Astellas inks $6B Iveric buyout ahead of FDA eye disease ruling
May 1, 2023 8:13am
Iveric eye disease study hits again, keeping it on Apellis' tail
Sep 6, 2022 8:00am
Iveric Bio's executive chair, founder Guyer steps down
Apr 5, 2021 8:20am
Iveric latest to be hit by COVID-19 as it delays a key trial
Mar 18, 2020 9:15am
Ophthotech (now Iveric) hits eye drug goals as shares jump
Oct 28, 2019 8:03am